UK markets close in 2 hours 21 minutes

UroGen Pharma Ltd. (0XOD.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
22.70-2.82 (-11.05%)
As of 5:27PM GMT. Market open.
Full screen
Previous close25.52
Open22.70
Bid0.00 x N/A
Ask0.00 x N/A
Day's range22.70 - 22.70
52-week range22.70 - 22.70
Volume4
Avg. volumeN/A
Market cap317.677M
Beta (5Y monthly)1.23
PE ratio (TTM)N/A
EPS (TTM)-6.37
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    UroGen Pharma Announces March 2021 Conference Schedule

    UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in March 2021:

  • UroGen Pharma Ltd. (NASDAQ:URGN): Are Analysts Optimistic?
    Simply Wall St.

    UroGen Pharma Ltd. (NASDAQ:URGN): Are Analysts Optimistic?

    We feel now is a pretty good time to analyse UroGen Pharma Ltd.'s ( NASDAQ:URGN ) business as it appears the company...

  • Business Wire

    UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer

    UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic three-year collaboration agreement to advance combinatorial intravesical immunotherapy, which is delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer (HG-NMIBC). UroGen’s approach involves the local delivery of potent immunomodulators (UGN-201, a TLR 7/8 agonist and UGN-301, an anti-CTLA-4 antibody). UGN-301, an immune checkpoint inhibitor, is delivered using UroGen’s proprietary RTGel™ platform to increase dwell time, which has been shown to significantly improve the effectiveness of intravesical therapy.